MeiraGTx Holdings plc
MGTX · Nasdaq · USD · Market cap $864M · 400 employees
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases.
PASS · Titan Ethical · score 93.7Price as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 12:17 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.98 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.94x the price, above our 2.00x limit.
- Our regime readDistribution, as of 17 Nov 2026
- Ethical screenPasses, score 93.7 out of 100
- OptionsOpen interest leans to puts (put/call 1.00)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Distribution
- Insiders insiders sold, $294,292, latest filing 2026-10-06
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.00, read 2026-11-20
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
MeiraGTx Holdings plc holds its Distribution at $7.98. The statistical read favours the sellers, held for 11 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 11 days |
| Price at the screen | $7.98 |
| Valuation | 10.34 trailing · -5.90 forward price to earnings |
| Values screen | PASS · score 93.7 |
| Beta | 1.07 |
Five Screens: MGTX's Results
PASS. All five recorded results clear their limits.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 9.61% | Below 33% | Pass |
| Interest-bearing cash | 7.14% | Below 33% | Pass |
| Receivables | 0.00% | Below 49% | Pass |
| Revenue purity | 2.23% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Clears, in Plain English
MeiraGTx clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when MGTX's ethical verdict changes
Today MGTX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.94x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet. Average target +194%.
| Forward P/E | -5.9x |
| Trailing P/E | 10.3xreasonably valued |
| EPS, trailing | 0.87 |
| EPS, forward | -1.53 |
| Revenue growth | +8,608.6%growing very fast |
| Profit margin | 19.9%healthy profit margins |
| Return on equity | 72.2%an exceptional return on shareholder capital |
| FCF yield | 6.53% |
| Debt to equity | 0.52moderate, manageable leverage |
| Current ratio | 3.76comfortably covers its short-term bills |
| Beta | 1.07moves a little more than the market |
| Short interest, float | 0.09% |
| 52-week range | 6.62 - 15.35 |
| Market cap | $864M |
| Employees | 400 |
MGTX-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markdown to distribution since the last review.
Earnings landed in this window. Ethical screening: PASS.
Written on its date, before the outcome; never pruned.
- MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates Yahoo Finance · 9d ago
- MeiraGTx Reports Third Quarter 2026 Financial and Operational Results Yahoo Finance · 9d ago
- MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting Yahoo Finance · 25d ago
- MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors Yahoo Finance · 23 Sep 2026
- What Could MeiraGTx Holdings (MGTX) New Hires And Profit Swing Signal? Simply Wall St. · 14 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY | S - Sale | 27,659 | $294,292 |
| 2026-05-19 | FORBES ALEXANDRIA | Chief Executive Officer | 62,000 | $568,540 | |
| 2026-04-21 | GIROUX RICHARD | Chief Operating Officer | 56,000 | $572,320 | |
| 2026-04-17 | PERCEPTIVE ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 555,555 | $4,999,995 | |
| 2026-04-07 | NAYLOR STUART | Officer | 27,661 | $258,907 | |
| 2026-03-24 | FORBES ALEXANDRIA | Chief Executive Officer | 62,000 | $459,420 | |
| 2026-02-20 | FORBES ALEXANDRIA | Chief Executive Officer | 62,500 | · | |
| 2026-02-20 | ZELDIN ROBERT K | Officer | 7,500 | · | |
| 2026-02-20 | GIROUX RICHARD | Chief Operating Officer | 60,000 | · | |
| 2026-02-20 | NAYLOR STUART | Officer | 25,000 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $9.90 | -8.7% | · | $913 | -8.7% |
| 2 months | $8.97 | +0.8% | · | $1,008 | +0.8% |
| 3 months | $7.64 | +18.3% | · | $1,183 | +18.3% |
| 6 months | $8.72 | +3.7% | · | $1,037 | +3.7% |
| 1 year | $6.86 | +31.8% | · | $1,318 | +31.8% |
| 2 years | $4.80 | +88.3% | · | $1,883 | +88.3% |
| 3 years | $8.07 | +12.0% | · | $1,120 | +12.0% |
| 5 years | $14.90 | -39.3% | · | $607 | -39.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MGTX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.